Highly halaven-resistant KBV20C cancer cells can be sensitized by co-treatment with fluphenazine

Anticancer Research

Volumn 36, Issue 11, 2016, Pages 5867-5874

  Cheon, Ji Hyun ^a   Lee, Byung Mu ^a   Kim, Hyung Sik ^a   Yoon, Sungpil ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Drug resistance; Fluphenazine; Halaven; Mefloquine; P gp; Thioridazine

Indexed keywords

AZATHIOPRINE; ERIBULIN; FLUPHENAZINE; HISTONE H2AX; HISTONE H3; LIPOCORTIN 5; MEFLOQUINE; MULTIDRUG RESISTANCE PROTEIN; RETINOBLASTOMA PROTEIN; THIORIDAZINE; VERAPAMIL; FURAN DERIVATIVE; KETONE;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIZATION; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC50; KB CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; TUMOR CELL LINE;

CELL LINE, TUMOR; FLUPHENAZINE; FURANS; HUMANS; KETONES;

EID: 84993971937     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11172     Document Type: Article

References (29)

1. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004.
2. McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785: 96-132, 2008.
3. Matsuo K, Bond VK, Im DD and Rosenshein NB: Prediction of chemotherapy response with platinum and taxane in the advanced stage of ovarian and uterine carcinosarcoma: A clinical implication of in vitro drug resistance assay. Am J Clin Oncol 33: 358-363, 2010.
4. Yang H and Dou QP: Targeting apoptosis pathway with natural terpenoids: Implications for treatment of breast and prostate cancer. Curr Drug Targets 11: 733-744, 2010.
5. Dell'Ova M, De Maio E, Guiu S, Roca L, Dalenc F, Durigova A, Pinguet F, Bekhtari K, Jacot W and Pouderoux S: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: Results from the ERIBEX retrospective, international, multicenter study. BMC cancer 15: 659, 2015.
6. Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, Orth JD, Mitchison TJ and Weissleder R: Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci Transl Med 6: 261ra152, 2014.
7. Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y and Takashima S: A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23: 1441-1448, 2012.
8. Dybdal-Hargreaves NF, Risinger AL and Mooberry SL: Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res 21: 2445-2452, 2015.
9. De Preter K, De Brouwer S, Van Maerken T, Pattyn F, Schramm A, Eggert A, Vandesompele J and Speleman F: Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin Cancer Res 15: 3690-3696, 2009.
10. Hwang MK, Min YK and Kim SH: Calmodulin inhibition contributes to sensitize TRAIL-induced apoptosis in human lung cancer H1299 cells. Biochem Cell Biol 87: 919-926, 2009.
11. Jaszczyszyn A, Gasiorowski K, Swiatek P, Malinka W, Cieslik-Boczula K, Petrus J and Czamik-Matusewicz B: New fluphenazine analogues as inhibitors of P-glycoprotein in human lymphocyte cultures. Contem Oncol 16: 332-337, 2012.
12. Yang JM, Sullivan GF, Makhey DB, LaVoie EJ and Hait WN: Inhibitory effect of alkylating modulators on the function of P-glycoprotein. Oncol Res 9: 477-484, 1997.
13. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, Hassell JA, Fischer-Russell D, Trus MR, Foley R, Leber B, Xenocostas A, Brown ED, Collins TJ and Bhatia M: Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149: 1284-1297, 2012.
14. Choi AR, Kim JH, Woo YH, Kim HS and Yoon S: Anti-malarial drugs primaquine and chloroquine have different sensitization effects with antimitotic drugs in resistant cancer cells. Anticancer Res 36: 1641-1648, 2016.
15. Hwang JW, Cho H, Lee JY, Jeon Y, Kim SN, Lee SJ, Bae GU, Yoon S, Jeon R and Kim YK: The synthetic ajoene analog SPA3015 induces apoptotic cell death through crosstalk between NF-kappaB and PPARgamma in multidrug-resistant cancer cells. Food Chem Toxicol 96: 35-42, 2016.
16. Kim NH, Kim SN, Oh JS, Lee S and Kim YK: Antimitotic potential of 7-diethylamino-3(2'-benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line snu620/5-fu. Biochem Biophy Res Commun 418: 616-621, 2012.
17. Choi AR, Jo MJ, Jung MJ, Kim HS and Yoon S: Selenate specifically sensitizes drug-resistant cancer cells by increasing apoptosis via G2 phase cell cycle arrest without P-GP inhibition. Eur J Pharmacol 764: 63-69, 2015.
18. Choi AR, Jung MJ, Kim JH and Yoon S: Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis. Anticancer Res 35: 4741-4747, 2015.
19. Choi AR, Kim JH and Yoon S: Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and p-gp inhibition. Tumour Biol 35: 9831-9838, 2014.
20. Rho SB, Kim BR and Kang S: A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol 120: 121-127, 2011.
21. Choi AR, Kim JH and Yoon S: Sensitization of cancer cells through reduction of total AKT and downregulation of salinomycin-induction of pAKT, pGSK3beta, pTSC2, and p4EBP1 by cotreatment with MK-2206. Biomed Res Int 2014: 295760, 2014.
22. Kim JH, Choi AR, Kim YK, Kim HS and Yoon S: Low amount of salinomycin Greatly increases AKT activation, but reduces activated p70S6K levels. Int J Mol Sci 14: 17304-17318, 2013.
23. Kim JH, Choi AR, Kim YK and Yoon S: Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition. Biochem Biophys Res Commun 441: 655-660, 2013.
24. Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carvalheira JB, Manunta S, Mazzarella L, Brollo J and Goldhirsch A: Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol 23: 547-555, 2012.
25. Kim JH, Chae M, Choi AR, Sik Kim H and Yoon S: SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. Eur J Pharmacol 723: 141-147, 2014.
26. Clark KB: New therapeutic bearings for repositioned drugs. Curr Top Med Chem 13: 2281-2282, 2013.
27. Pantziarka P and Cairns L: Recycling existing drugs for cancer therapy: delivering low cost cancer care. Ecancermedicalscience 8: ed40, 2014.
28. Cieslik-Boczula K, Swiatek P, Jaszczyszyn A, Zawilska P, Gasiorowski K, Malinka W and Kohler G: Phase separation in phosphatidylcholine membrane caused by the presence of a pyrimidine analogue of fluphenazine with high anti-multidrug-resistance activity. J Phys Chem B 118: 3605-3615, 2014.
29. Qi L and Ding Y: Potential antitumor mechanisms of phenothiazine drugs. Sci China Life Sci 56: 1020-1027, 2013.